Hedgehog, Notch and Wnt developmental pathways as targets for anti-cancer drugs

Drug Discovery Today: Disease Mechanisms

Volumn 4, Issue 4, 2007, Pages 285-291

  Muller, Jean Marc ^a   Chevrier, Lucie ^a   Cochaud, Stéphanie ^a   Meunier, Annie Claire ^a   Chadeneau, Corinne ^a  

^a UNIVERSITÉ DE POITIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CELECOXIB; CYCLOPAMINE; GAMMA SECRETASE INHIBITOR; INDOMETACIN; MK 0752; NONSTEROID ANTIINFLAMMATORY AGENT; NOTCH RECEPTOR; RESVERATROL; SONIC HEDGEHOG PROTEIN; WNT PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOMATOUS POLYP; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BASAL CELL CARCINOMA; CARCINOGENESIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; GLIOMA; HUMAN; LUNG CANCER; LYMPHOMA; MEDULLOBLASTOMA; MELANOMA; NONHUMAN; PROTEIN EXPRESSION; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION;

EID: 47049095475     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2008.05.009     Document Type: Review

References (34)

1. Ingham P.W., and McMahon A.P. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 15 (2001) 3059-3087
2. Nickoloff B.J., et al. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22 (2003) 6598-6608
3. Nelson W.J., and Nusse R. Convergence of Wnt, β-catenin, and cadherin pathways. Science 303 (2004) 1483-1487
4. Briscoe J., and Therond P. Hedgehog signaling: from the Drosophila cuticle to anti-cancer drugs. Developmental Cell 8 (2005) 143-151
5. Reya T., and Clevers H. Wnt signaling in stem cells and cancer. Nature 34 (2005) 843-850
6. Mimeault M., et al. Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J. Cell. Mol. Med. 11 (2007) 981-1011
7. Peacock C.D., et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 4048-4053
8. Ruiz I. Altaba A., et al. The Gli code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol. 17 (2007) 438-447
9. Hutchin M.E., et al. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev. 19 (2005) 214-223
10. Bhatia N., et al. Gli2 is targeted for ubiquitination and degradation by beta-TrCP ubiquitin ligase. J. Biol. Chem. 28 (2006) 19320-19326
11. Kasai K., et al. The G12 family of heterotrimeric G proteins and Rho GTPase mediate Sonic hedgehog signaling. Genes Cells 9 (2005) 49-58
12. Lauth M., and Toftgard R. Non-canonical activation of GLI transcription factors. Cell Cycle 6 (2007) 2458-2463
13. Stecca B., and Ruiz I. Altaba A. The therapeutic potential of modulators of the Hedgehog-Gli signaling pathway. J. Biol. 1 (2002) 9
14. Stecca B., et al. Interference with HH-GLI signaling inhibits prostate cancer. Trends Mol. Med. 11 (2005) 199-203
15. Sun S., et al. New molecularly targeted therapies for lung cancer. J. Clin. Invest. 117 (2007) 2740-2750
16. Katoh M. WNT/PCP signaling pathway and human cancer (review). Oncol. Rep. 4 (2005) 1583-1588
17. Cadigan K.M., and Liu Y.I. Wnt signaling: complexity at the surface. J. Cell Sci. 119 (2006) 395-402
18. Katoh M., and Katoh M. WNT signaling pathway and stem cell signaling network. Clin. Cancer Res. 13 (2007) 4042-4045
19. Takahashi-Yanaga F., and Sasaguri T. The Wnt/beta-catenin signaling pathway as a target in drug discovery. J. Pharmacol. Sci. 104 (2007) 293-302
20. Polakis P. The many ways of Wnt in cancer. Curr. Opin. Genet. Dev. 17 (2007) 45-51
21. Aguilera O., et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 25 (2006) 4116-4121
22. Batra S., et al. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem. Biophys Res. Commun. 342 (2006) 1228-1232
23. Caldwell G.M., et al. The Wnt antagonist sFRP1 is downregulated in premalignant large bowel adenomas. Br. J. Cancer 94 (2006) 922-927
24. Muller J.M. Potential inhibition of the neuro-neoplastic interactions: the clue of a GPCR-targeted therapy. Prog. Exp. Tumor Res. 39 (2007) 130-153
25. Fiúza U.M., and Arias A.M. Cell and molecular biology of Notch. J. Endocrinol. 194 (2007) 459-474
26. Kovall R.A. Structures of CSL, Notch and Mastermind proteins: piecing together an active transcription complex. Curr. Opin. Struct. Biol. 17 (2007) 117-127
27. Giehl K.M. Neuronal development. Prog. Exp. Tumor. Res. 39 (2007) 1-29
28. Shih L.M., and Wang T.L. Notch signaling, secretase inhibitors, and cancer therapy. Cancer Res. 67 (2007) 1879-1882
29. Fan X., et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 66 (2006) 7445-7452
30. Lauth M., and Toftgård R. The Hedgehog pathway as a drug target in cancer therapy. Curr. Opin. Investig. Drugs 8 (2007) 457-461
31. Kiselyov A.S., et al. Small-molecule modulators of Hh and Wnt signaling pathways. Expert Opin. Ther. Targets 11 (2007) 1087-1101
32. Kiselyov A.S. Targeting the hedgehog signaling pathway with small molecules. Anticancer Agents Med. Chem. 6 (2006) 445-449
33. Katoh M. Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev. 3 (2007) 30-38
34. Lauth M., et al. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 8455-8460